IN2014DN11027A - - Google Patents

Info

Publication number
IN2014DN11027A
IN2014DN11027A IN11027DEN2014A IN2014DN11027A IN 2014DN11027 A IN2014DN11027 A IN 2014DN11027A IN 11027DEN2014 A IN11027DEN2014 A IN 11027DEN2014A IN 2014DN11027 A IN2014DN11027 A IN 2014DN11027A
Authority
IN
India
Prior art keywords
compound
treatment
subunit
disorders
responsive
Prior art date
Application number
Other languages
English (en)
Inventor
Janus Schreiber Larsen
Magnus Gustafsson
Carsten Jessen
Original Assignee
Aniona Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aniona Aps filed Critical Aniona Aps
Publication of IN2014DN11027A publication Critical patent/IN2014DN11027A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN11027DEN2014 2012-06-26 2013-06-25 IN2014DN11027A (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664288P 2012-06-26 2012-06-26
DKPA201270369 2012-06-26
PCT/EP2013/063194 WO2014001282A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
IN2014DN11027A true IN2014DN11027A (OSRAM) 2015-09-25

Family

ID=49782300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11027DEN2014 IN2014DN11027A (OSRAM) 2012-06-26 2013-06-25

Country Status (13)

Country Link
US (2) US9475797B2 (OSRAM)
EP (1) EP2885290B1 (OSRAM)
JP (1) JP6223443B2 (OSRAM)
KR (1) KR20150033679A (OSRAM)
CN (1) CN104411703A (OSRAM)
AU (1) AU2013283488A1 (OSRAM)
BR (1) BR112014032501A2 (OSRAM)
CA (1) CA2876780A1 (OSRAM)
IL (1) IL235991A (OSRAM)
IN (1) IN2014DN11027A (OSRAM)
MX (1) MX2014014872A (OSRAM)
RU (1) RU2014149123A (OSRAM)
WO (1) WO2014001282A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
PH12022552340A1 (en) 2020-03-26 2023-11-29 Richter Gedeon Nyrt APHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA a5 RECEPTOR MODULATORS
JP7739336B2 (ja) * 2020-05-13 2025-09-16 エフ. ホフマン-ラ ロシュ アーゲー Gaba a alpha5 pamとしての新規トリアゾリル誘導体
EP3992188A1 (en) * 2020-10-29 2022-05-04 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116462664B (zh) * 2022-03-08 2025-07-01 上海赛默罗生物科技有限公司 吡唑环类化合物、其制备方法、组合物及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091346B1 (en) 1995-11-01 2006-08-15 Novartis Ag Purine derivatives and processes for their preparation
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
CA2314401A1 (en) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
JP2004501062A (ja) 1999-12-17 2004-01-15 アライアッド・ファーマシューティカルズ・インコーポレーテッド 新規プリン類
CA2394654A1 (en) 1999-12-17 2001-06-21 Manfred Weigele Proton pump inhibitors
AU2441701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Purine derivatives
GB2378180B8 (en) 2001-06-27 2009-10-21 Cyclacel Ltd New purine derivatives
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
US20030229105A1 (en) 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ[2,3−d]ピリミジン−4−イルおよびプリン−6−イル尿素化合物
MXPA06001758A (es) 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
EP1881991A1 (en) 2005-05-19 2008-01-30 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007039389A1 (en) 2005-09-19 2007-04-12 F. Hoffmann-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
CN101277952B (zh) 2005-10-11 2011-09-28 弗·哈夫曼-拉罗切有限公司 异*唑衍生物
EP1948648B1 (en) 2005-11-09 2010-05-05 F.Hoffmann-La Roche Ag 3-aryl-isoxazole-4-carbonyl-benzofurane derivatives
WO2007071632A2 (en) 2005-12-20 2007-06-28 Neurosearch A/S 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
ATE537171T1 (de) 2005-12-27 2011-12-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
JP2009521516A (ja) 2005-12-27 2009-06-04 エフ.ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾール−4−イル−イミダゾール誘導体
AR061101A1 (es) * 2006-05-24 2008-08-06 Lilly Co Eli Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende
JP5087616B2 (ja) 2006-05-31 2012-12-05 エフ.ホフマン−ラ ロシュ アーゲー アリール−4−エチニル−イソオキサゾール誘導体
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
JP2010502674A (ja) 2006-09-07 2010-01-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
MX2009007944A (es) 2007-01-26 2009-08-07 Irm Llc Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
EP2114916A2 (en) 2007-02-02 2009-11-11 NeuroSearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
EP2142547A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
NZ579248A (en) 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
EP2170873B1 (en) 2007-06-22 2011-08-10 F. Hoffmann-La Roche AG Isoxazole-imidazole derivatives
BRPI0818578A2 (pt) 2007-10-17 2015-07-21 Novartis Ag Derivados de purina como ligantes receptores de adenosina a1
PT2767536E (pt) 2007-12-04 2015-11-17 Hoffmann La Roche Derivados de isoxazolo-piridina
EP2229383B1 (en) 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
CN103373985B (zh) * 2008-06-19 2015-10-28 武田药品工业株式会社 杂环化合物及其用途
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US20110237607A1 (en) 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
JP5460858B2 (ja) 2009-05-05 2014-04-02 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピラゾール誘導体
EP2427458B1 (en) * 2009-05-05 2014-05-07 F.Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
AU2010244551A1 (en) 2009-05-05 2011-12-01 F. Hoffmann-La Roche Ag Isoxazole-thiazole derivatives as GABA A receptor inverse agonists for use in the treatment of cognitive disorders
CN102414206B (zh) 2009-05-05 2014-11-05 霍夫曼-拉罗奇有限公司 异*唑-吡啶衍生物
WO2010127978A1 (en) 2009-05-07 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as gaba modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
BR112013011265A2 (pt) * 2010-11-09 2016-11-01 Hoffmann La Roche derivados de triazol como ligantes para receptores gaba
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Also Published As

Publication number Publication date
CA2876780A1 (en) 2014-01-03
EP2885290A1 (en) 2015-06-24
US9475797B2 (en) 2016-10-25
AU2013283488A1 (en) 2015-01-15
CN104411703A (zh) 2015-03-11
JP6223443B2 (ja) 2017-11-01
IL235991A (en) 2017-07-31
IL235991A0 (en) 2015-02-01
US20160115155A1 (en) 2016-04-28
JP2015521643A (ja) 2015-07-30
MX2014014872A (es) 2015-08-06
BR112014032501A2 (pt) 2017-06-27
US9884848B2 (en) 2018-02-06
US20170114045A1 (en) 2017-04-27
EP2885290B1 (en) 2017-10-18
KR20150033679A (ko) 2015-04-01
RU2014149123A (ru) 2016-08-20
WO2014001282A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
MX357504B (es) Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
MD20150091A2 (ro) Compuşi antivirali
IN2015DN00847A (OSRAM)
PH12016500094A1 (en) Autotaxin inhibitors
IN2014MN02459A (OSRAM)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
JO3334B1 (ar) مشتقات أوكسازوليدين-2- أون – بيريميدين
IN2015DN00372A (OSRAM)
MD4583B1 (ro) Piridinone biciclice noi
IN2014DN11027A (OSRAM)
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
PH12017500089B1 (en) Aldosterone synthase inhibitors
IN2014CN03854A (OSRAM)
PH12017500595A1 (en) Aldosterone synthase inhibitors
IN2013DN02555A (OSRAM)
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
WO2012174552A3 (en) Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
IN2014KN00849A (OSRAM)
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production